A Narrative Review on the Management of Severe COVID-19 Infection Using Stem Cell-based therapies with a Focus on the Registered Clinical Trials

Negin Mahmoudi\textsuperscript{1}, Negar Mohammadi Ganjaroudi\textsuperscript{1}, Alireza Soltani Khaboushan\textsuperscript{1}, Elham Ahmadi\textsuperscript{1}, Masoud Bitaraf\textsuperscript{1}, Asma Laleh\textsuperscript{2}, Shayesteh Mehdinejadiani\textsuperscript{3}, Masoumeh Majidi Zolbin\textsuperscript{1}

\textsuperscript{1}Tehran University of Medical Sciences
\textsuperscript{2}University of Tabriz
\textsuperscript{3}Shiraz University of Medical Sciences

\textbf{Funding:} No specific funding was received for this work.

\textbf{Potential competing interests:} No potential competing interests to declare.

\section*{Abstract}

The emergence of SARS-CoV-2 has led to a concerning global pandemic. The severity of COVID-19 symptoms may be enhanced due to underlying medical conditions. Several studies demonstrated severe COVID-19 infection can lead to innate and adaptive immune dysregulation, hypercytokinemia as well and the formation of fibro myxoid exudate in the respiratory alveolar, ultimately resulting in pulmonary fibrosis and ARDS as the leading cause of mortality and morbidity. Currently, there is a widespread global endeavor in finding efficient drugs or vaccines to manage COVID-19. Although some FDA-approved treatments have been introduced for COVID-19, alternative therapies might decrease the mortality rates. Various sources of stem cell-derived exosomes, pluripotent stem cells, and mesenchymal stem cells as cell-based therapies have been applied to moderate to severe COVID-19 patients with ARDS, leading to positive results. Cell-based therapies can probably inhibit tissue remodeling and subsequent end-organ damage by modulating the cytokine cascades and cellular apoptosis. The present review aims to discuss the advantages of stem cell-based therapies in the treatment of COVID-19 patients and the possible challenges associated with their application.
Running Title: COVID-19 and Stem Cell Therapy

Keywords: COVID-19, SARS-CoV-2, Stem cells, Inflammation, Cytokines, Tissue regeneration.

Abbreviations

- AAT: Alpha-1-antitrypsin.
- ACE2: Angiotensin convertase enzyme 2.
- ADMSCs: Adipose-derived mesenchymal stem cells.
- ALI: Acute lung injury.
- AlloHSC-iNKT: Allogeneic hematopoietic stem cell-engineered invariant natural killer T cells.
- ARDS: Acute respiratory distress syndrome.
- AT2: Alveolar type 2 pneumocyte.
- bFGF: Basic fibroblast growth factor.
- BM-MSC: Bone marrow-derived mesenchymal stem cell.
- BMP4: Bone morphogenetic protein 4.
- BW: Body weight.
- CCL2: C-C motif chemokine ligand-2.
- CT-Scan: Computed tomography scan.
- CXC4: Chemokine receptor 4.
- CXC7: Chemokine receptor 7.
- CXCL12: C-X-C motif chemokine-12.
- DCs: Dendritic cells.
- 3D-HLO: Three-dimensional human lung organoid.
- DPSC: Dental pulp stem cells.
- ECMO: Extra-corporeal membrane oxygenation.
- EGF: Epidermal growth factor.
• EP2: E-prostanoid 2.
• ESCs: Embryonic stem cells.
• EVs: Extracellular vesicles.
• FDA: United States Food and Drug Administration.
• FGF10: Fibroblast growth factor 10.
• FiO2: Fraction of inspired oxygen.
• GMP: Good Manufacturing Practices.
• hiPSCs: Human-induced pluripotent stem cells.
• HO-1: Heme oxygenase-1.
• hPBSCs: Human peripheral blood-derived stem cells.
• hP-MSC: Human placenta-derived mesenchymal stem cell.
• HSC: Hematopoietic stem cell.
• hUC-MSCs: Human umbilical cord-derived mesenchymal stem cells.
• hWJ-MSC-S: Human Wharton’s Jelly Mesenchymal Stem Cells Secretome.
• IFN-β1: Interferon-β1.
• iNKT cells: Invariant natural killer T cells.
• IL-6: Interleukin-6.
• IL-10: Interleukin 10.
• IL-18: Interleukin-18.
• KGF1: Keratinocyte growth factor 1.
• KLF4: Kruppel-like factor 4.
• MAPK: Mitogen-activated protein kinase.
• MenSCs secretome: Menstrual blood-derived mesenchymal stem cells secretome.
• MMP-1: Matrix metalloproteinase-1.
• MOF: Multiple organ failure.
• MSCs: Mesenchymal stem cells.
• NF-κB: Nuclear factor kappa B.
• NHPBSCs: Non-hematopoietic peripheral blood stem cells.
• NKKX2.1: NK2 homeobox 1.
• PaO2: Partial pressure of oxygen.
• PB plasma/SCs: Peripheral Blood Stem Cells and Plasma stem cells.
• PCL: Polycaprolactone.
• PCR: Polymerase chain reaction.
• PLG: Poly lactide-co-glycolide.
• RA: Retinoic acid.
• SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.
• SPO2: Oxygen Saturation.
1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to beta-coronaviruses from the Coronaviridae family [1], which recently caused the Coronavirus Disease 2019 (COVID-19) pandemic as a global emergency [2][3]. The coronaviruses have four genera: alpha-, beta-, gamma-, and delta-coronaviruses. Alpha-/beta-coronaviruses are responsible for infections in mammalian species, gamma-coronavirus in avian species, and delta-coronavirus in both avian species and mammals [4][5]. Viral pneumonia resulting from the COVID-19 outbreak was first reported in December 2019 [6]. Helical nucleocapsid protein (N) surrounding the lipid envelopes packs the viral genome [7]. The SARS-CoV-2 binding proteins are characterized by clove-shape spikes called 'corona'. The binding proteins consist of the host cell receptor-binding subunit (S1) and the host cell membrane-fusion subunits (S2). The aforementioned virus attaches to the human host cell receptors, to penetrate the host cell and integrate its genome with that of the host cell to ultimately replicate [8][9]. Despite the high rate of mutation in RNA viruses, SARS-CoV-2 as an RNA virus, has lower mutation rates due to genome-encoded exonuclease; hence, the SARS-CoV-2 has higher adaptivity, leading to more effective human-to-human transmission [10].

The severity of SARS-CoV-2 infection is categorized by symptoms and laboratory findings. A severe case of COVID-19 is characterized by the presence of respiratory distress, oxygen saturation (SPO2) lower than 93%, and partial pressure of oxygen (PaO2) to fraction of inspired oxygen (FiO2) ratio less than 300 mmHg [11]. COVID-19 can lead to severe complications such as severe thrombocytopenia and multiple organ failure (MOF). Respiratory failure and MOF are the leading causes of mortality in these populations [12][13][14][15].

Although there are comprehensive evaluations on different United States Food and Drug Administration (FDA)-approved therapeutic agents, including hydroxychloroquine, convalescent plasma, interferon-β1 (IFN-β1), lopinavir/ritonavir, and remdesivir in the COVID-19 treatment; still, there are controversies about their efficacy and safety [16][17]. Several biomaterial-produced agents are studied to strengthen or assist the anti-viral effects of other therapeutic agents, such as silver nanoparticles, and two tetradentate dibasic chelating Schiff base iron III [18][19].
The destructive nature, dangerous complications, and adverse impact on the world economy highlight the necessity of finding a novel and efficient candidate to manage this disease [20], reduce the mortality rate, and achieve better recovery, especially in moderate to severe cases [21]. There has been a growing interest in the use of stem cell-based therapies including stem cell-derived exosomes, induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs) in the treatment of COVID-19 [22][23][24][25]. Human-induced pluripotent stem cells (hiPSCs) which are derived from somatic cells, have been identified as a suitable source for cell therapy, particularly in the context of infectious diseases, compared to other types of stem cells [26]. Additionally, the anti-inflammatory and immunomodulatory properties of MSCs make them an attractive option for treating COVID-19 [27][28][29]. There is a growing interest in stem cell-derived exosome applications trialed as treatment options for COVID-19 due to lower immunogenic, stable characteristics and less invasive harvesting process. Stem cell-derived exosomes can delay the inflammatory effects of the virus by providing immunomodulatory effects or functioning as Nano decoys. The immunomodulatory effects of exosomes can be included as inhibiting the macrophage’s TNF-α production, decreasing neutrophil migration, and lowering lung fibrosis stimulator (Ly6chi monocytes) [25][30][31].

Accordingly, because of limited data available on the clinical applications of stem cells to manage COVID-19, the present review aims to discuss the advantages and beneficial effects of stem cells, including hiPSCs and MSCs, in the treatment of this infectious disease and the challenges as may arise as a result in this context.

2. Rationale for stem cell-based therapies in COVID-19

Regenerative medicine and Tissue engineering are cell-based therapeutic approaches in which the injured tissues and organs are regenerated or replaced using stem cells via cell-loaded and 3-D constructs or platforms [32]. The capability of regulating inflammatory reactions, and enhancing tissue repair, and regeneration are stem cells features [33]. Several retrospective studies demonstrated that patients who died of COVID-19 had higher serum concentrations of inflammatory markers such as interleukin-6 (IL-6) [34][35][36]. The Hypercytokinemia syndrome characterized by the hypersecretion of inflammatory cytokines; is responsible for acute cardiac damage, renal failure, acute respiratory distress syndrome (ARDS), air exchange dysfunction, pulmonary edema, and increasing mortality rates in COVID-19 [11][36]. Effective therapeutic options are lacking in the cases of severe SARS-CoV-2 infection to ameliorate the respiratory complications and hyperinflammatory syndrome. Current care management in severe cases of COVID-19 pneumonia such as anti-viral drugs, extracorporeal membrane oxygenation (ECMO), and ventilator-assisted oxygenation cannot reverse the formation of fibromyxoid exudate in respiratory alveolars and subsequent alveolar fibrosis [36][37]. Despite effective therapy, acute respiratory distress syndrome (ARDS) is the leading cause of mortality and morbidity in severe SARS-CoV-2 infection. An in vitro study evaluating the characteristics of SARS-CoV-2-exposed induced pluripotent stem cells (iPSCs) demonstrated that the exposed stem cells formed a fibroblast-like phenotype and lost their pluripotent [38]. Several studies depicted that the MSCs application in ARDS models can decrease the alveolar fluid accumulation by repairing and protecting alveolar epithelial and endothelial cells, decreasing endothelial and epithelial permeability, and ultimately ameliorating the alveolar fibrosis [36][39][40]. Some of the therapeutic potentials of stem cell-based therapies in COVID-19 pneumonia are the ability
to balance immune responses as well as regulate hypercytokinemia, the recovery of the lung microenvironment, the protection of alveolar epithelial cells, and the alteration of lung dysfunction. Therefore, stem cell-based therapies can be used as an alternative therapy in cases of moderate to severe COVID-19 infection \[41\]. MSC could be an appropriate candidate to modulate the complications created by SARS-CoV-2 because of its anti-inflammatory and immunomodulatory effects \[42\]. Determining the type and source of stem cells for therapeutic applications is of great importance in terms of efficacy and safety in the COVID-19 treatment \[43\].

Limited multinational well-designed studies have been performed to evaluate precise involved mechanisms of stem cell-based therapies in patients with ARDS or SARS-CoV-2 induced pneumonia. Various studies have faced daunting challenges and limitations in evaluating and interpreting the efficacy of different pharmacological agents in COVID-19 management, such as drug side effects, insignificant suppression of viral loads as the primary outcomes, co-treatments and drug delivery routes, temporary comorbidities, no gender considerations, no placebo-control arm, and small cohort sizes. Stem cell-based therapies could be an alternative route in finding treatment strategies \[44\][45][46]. Figure 1 depicts an overview of various sources of stem cell application in COVID-19 infection.

Figure 1. An overview of the application of the various stem cells in the modeling and treatment of COVID-19. Various types of mesenchymal stem cells and induced pluripotent mesenchymal stem cells can be applied as a platform of the COVID-19 in-vitro models for evaluating the effectiveness of different drugs on the diseased model as well as studying underlying pathophysiologic mechanisms. The Abbreviations: DPSC, dental pulp stem cells; ADMSC, adipose-derived mesenchymal stem cells; BM-MSC, bone marrow-derived mesenchymal stem cell; P-MSC, placenta-derived
3. Recent stem cell-based studies in the treatment of COVID-19

Many countries such as the United States and China have conducted clinical trials to evaluate the safety and efficacy of stem cell products in treating moderate to severe cases of COVID-19 (Table 1, Table 2). In the conducted clinical trials, stem cells and their products were applied as interventional arms, as shown in Table 1 and Table 2, respectively. There were variable reports of cell doses and protocols. In 28 out of 58 clinical trials, the number of cells used in the interventional arms was based on the patient’s weight, whereas in other trials, the number of applied cells was regardless of the patient’s weight. Different types of stem cells are being applied as an interventional arm, ranging from embryonic stem cells to mesenchymal stem cells [47][48].

Beneficial therapeutic effects of mesenchymal stem cells in the treatment of COVID-19 are being evaluated by many clinical trials, most of which are injected intravenously, except for 6 clinical trials in which the administration of MSCs and MSC-derived exosomes have been suggested through the inhalation route [7]. Among several clinical trials evaluating the safety and efficacy of stem cell therapy in COVID-19, four completed trials suggested improvements in clinical outcomes without increasing adverse events (Table 1). The completed trials referenced as NCT04473170 and NCT04355728 using non-hematopoietic peripheral blood stem cells (NHPBSCs) and umbilical cord-derived mesenchymal stem cells (UCMSCs) demonstrated improving clinical outcomes without increasing adverse effects with the overall survival rates of 94.20% and 91%, respectively. A study referenced as NCT05019287 depicted that MenSCs secretome could be beneficial in reversing hypoxia and reducing the COVID-19 infection mortality rates. The completed clinical trial referenced as IRCT20160809029275N1 demonstrated promising results regarding the presence of recovery in moderate to severe patients receiving more than one dosage of UCMSCs IV injection by forming a significant decrease in the inflammatory cytokine levels [49]. The outcome of conducted clinical trials is categorized into primary and secondary outcomes. The evaluated outcomes through the conducted clinical trials are assessment of pulmonary index, Sequential organ failure score, inflammatory markers level, presence and frequency of adverse events, vital signs, clinical symptoms, short-term and long-term mortality rates, duration of ventilator-free days, hospitalization duration and assessment of radiologic improvement such as disappearing time of ground glass opacity.

<table>
<thead>
<tr>
<th>No.</th>
<th>Clinical trial identifier</th>
<th>country</th>
<th>Study design</th>
<th>Study phase</th>
<th>Current status</th>
<th>Source of stem cell</th>
<th>Route of delivery</th>
<th>Number of doses</th>
<th>Single-dose concentration (cells)</th>
<th>Dose intervals</th>
<th>Estimated enrollment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NCT04313322</td>
<td>Jordan</td>
<td>single-arm, open-label</td>
<td>phase 1</td>
<td>unknown (previously: recruiting)</td>
<td>WJ-MSCs</td>
<td>IV</td>
<td>3</td>
<td>1* 10 e6 /Kg</td>
<td>3 d</td>
<td>5</td>
</tr>
<tr>
<td>2</td>
<td>NCT04473170</td>
<td>United Arab Emirates</td>
<td>double arm, open label</td>
<td>phase 1/phase 2</td>
<td>completed</td>
<td>NHPBSCs</td>
<td>jet nebulization</td>
<td>2</td>
<td>2.2* 10 e6</td>
<td>1 d</td>
<td>146</td>
</tr>
<tr>
<td>Study ID</td>
<td>Country</td>
<td>Study Design</td>
<td>Study Type</td>
<td>Phase</td>
<td>Masking</td>
<td>Recruitment Status</td>
<td>Study Type</td>
<td>Intervention</td>
<td>Dose</td>
<td>Interval</td>
<td>Duration</td>
</tr>
<tr>
<td>-------------</td>
<td>-----------</td>
<td>--------------</td>
<td>------------</td>
<td>-------</td>
<td>---------</td>
<td>-------------------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
</tr>
<tr>
<td>NCT04428801</td>
<td>NM</td>
<td>double arm, double masking</td>
<td>phase 2</td>
<td>not yet recruiting</td>
<td>ADMSCs</td>
<td>IV</td>
<td>3</td>
<td>2**10 e8</td>
<td>3 d</td>
<td>200</td>
<td></td>
</tr>
<tr>
<td>NCT04444271</td>
<td>Pakistan</td>
<td>double arm, open label</td>
<td>phase 2</td>
<td>recruiting</td>
<td>BMSCs</td>
<td>NM</td>
<td>2</td>
<td>2**10 e6 /Kg</td>
<td>7 d</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>NCT04336254</td>
<td>China</td>
<td>double arm, triple masking</td>
<td>phase 1/phase 2</td>
<td>recruiting</td>
<td>hDPSCs</td>
<td>IV</td>
<td>3</td>
<td>3**10 e7</td>
<td>3 d</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>NCT04713878</td>
<td>Turkey</td>
<td>triple arm, open-label</td>
<td>not applicable</td>
<td>completed</td>
<td>MSCs</td>
<td>IV</td>
<td>3</td>
<td>1**10 e6 /Kg</td>
<td>2 d</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>NCT04302519</td>
<td>China</td>
<td>single-arm, open-label</td>
<td>early phase 1</td>
<td>unknown (previously: not yet recruiting)</td>
<td>DPMSCs</td>
<td>IV</td>
<td>3</td>
<td>1**10 e6 /Kg</td>
<td>4 d</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>NCT04429763</td>
<td>Colombia</td>
<td>double arm, double masking</td>
<td>phase 2</td>
<td>not yet recruiting</td>
<td>UCMSCs</td>
<td>IV</td>
<td>1</td>
<td>1**10 e6 /Kg</td>
<td>no intervals</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>NCT04486001</td>
<td>USA</td>
<td>single-arm, open-label</td>
<td>phase 1</td>
<td>recruiting</td>
<td>ADMSCs</td>
<td>IV</td>
<td>1</td>
<td>NM</td>
<td>no intervals</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>NCT04315987</td>
<td>Brazil</td>
<td>double arm, quadruple masking</td>
<td>phase 2</td>
<td>unknown (previously: not yet recruiting)</td>
<td>MSCs</td>
<td>IV</td>
<td>4</td>
<td>2**10 e7</td>
<td>2 d</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>NCT04416139</td>
<td>Mexico</td>
<td>double arm, open-label</td>
<td>phase 2</td>
<td>Recruiting</td>
<td>MSCs</td>
<td>IV</td>
<td>1</td>
<td>1**10 e6 /Kg</td>
<td>no intervals</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>NCT05017298</td>
<td>NM</td>
<td>double arm, quadruple masking</td>
<td>phase 2</td>
<td>not yet recruiting</td>
<td>ADMSCs</td>
<td>IV</td>
<td>3</td>
<td>2**10 e8</td>
<td>3 d</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>NCT04456361</td>
<td>Mexico</td>
<td>single-arm, open-label</td>
<td>early phase 1</td>
<td>active, not yet recruiting</td>
<td>WJ-MSCs</td>
<td>IV</td>
<td>1</td>
<td>1**10 e8</td>
<td>no intervals</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>NCT04437823</td>
<td>Pakistan</td>
<td>double arm, open label</td>
<td>phase 2</td>
<td>Recruiting</td>
<td>UCMSCs</td>
<td>IV</td>
<td>3</td>
<td>0.5**10 e6 /Kg</td>
<td>2 d</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>NCT04371601</td>
<td>China</td>
<td>double arm, open-label</td>
<td>early phase 1</td>
<td>active, not yet recruiting</td>
<td>UCMSCs</td>
<td>IV</td>
<td>4</td>
<td>1**10 e6 /Kg</td>
<td>1 d</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>NCT04611256</td>
<td>Mexico</td>
<td>double arm, open-label</td>
<td>phase 1</td>
<td>Recruiting</td>
<td>ADMSCs</td>
<td>IV</td>
<td>2</td>
<td>1**10 e6 /Kg</td>
<td>2 d</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>NCT04252118</td>
<td>China</td>
<td>double arm, open-label</td>
<td>phase 1</td>
<td>Recruiting</td>
<td>UCMSCs</td>
<td>IV</td>
<td>3</td>
<td>3**10 e7</td>
<td>3 d</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Study ID</td>
<td>Country</td>
<td>Design</td>
<td>Label</td>
<td>Phase</td>
<td>Status</td>
<td>Cell Type</td>
<td>Route</td>
<td>Dose (cells/Kg)</td>
<td>Interval</td>
<td>Duration</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>-----------</td>
<td>--------</td>
<td>-------------------</td>
<td>-------</td>
<td>----------------</td>
<td>-----------</td>
<td>-------</td>
<td>----------------</td>
<td>----------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>NCT04346368</td>
<td>China</td>
<td>double arm, single masking</td>
<td>phase 1/phase 2</td>
<td>not yet recruiting</td>
<td>BMSCs</td>
<td>IV</td>
<td>1* 10^6</td>
<td>no intervals</td>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT04273646</td>
<td>China</td>
<td>double arm, open-label</td>
<td>not applicable</td>
<td>not yet recruiting</td>
<td>UCMSCs</td>
<td>IV</td>
<td>0.5 * 10^6</td>
<td>2 d</td>
<td>48</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT04366323</td>
<td>Spain</td>
<td>double arm, open-label</td>
<td>phase 1/phase 2</td>
<td>active, not yet recruiting</td>
<td>ADMSCs</td>
<td>NM</td>
<td>8* 10^6</td>
<td>not mentioned</td>
<td>26</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT04625738</td>
<td>France</td>
<td>double arm, quadruple masking</td>
<td>phase 2</td>
<td>Completed</td>
<td>WJ-MSCs</td>
<td>IV</td>
<td>3</td>
<td>first dose: 1* 10^6 (maximum: 80 * 10^6), other doses: 0.5* 10^6 (maximum: 40 * 10^6)</td>
<td>2-3 d</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>NCT04905836</td>
<td>USA</td>
<td>double arm, quadruple masking</td>
<td>phase 2</td>
<td>Recruiting</td>
<td>ADMSCs</td>
<td>IV</td>
<td>3</td>
<td>3* 10^7</td>
<td>2 d</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>NCT04992247</td>
<td>NM</td>
<td>double arm, quadruple masking</td>
<td>phase 2</td>
<td>not yet recruiting</td>
<td>ADMSCs</td>
<td>IV</td>
<td>3</td>
<td>1.5* 10^7</td>
<td>2 d</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>NCT04457609</td>
<td>Indonesia</td>
<td>double arm, triple masking</td>
<td>phase 1</td>
<td>Recruiting</td>
<td>UCMSCs</td>
<td>IV</td>
<td>1</td>
<td>1* 10^6</td>
<td>no intervals</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>NCT04527224</td>
<td>NM</td>
<td>single-arm, open-label</td>
<td>phase 1/phase 2</td>
<td>not yet recruiting</td>
<td>ADMSCs</td>
<td>NM</td>
<td>NM</td>
<td>NM</td>
<td>NM</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>NCT05132972</td>
<td>Indonesia</td>
<td>double arm, quadruple masking</td>
<td>phase 2/phase 3</td>
<td>Recruiting</td>
<td>UCMSCs</td>
<td>IV</td>
<td>3</td>
<td>1* 10^6</td>
<td>3 d</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>NCT04494386</td>
<td>USA</td>
<td>triple arm, triple masking</td>
<td>phase 1/phase 2</td>
<td>Recruiting</td>
<td>UCMSCs</td>
<td>IV</td>
<td>1 or 2</td>
<td>1* 10^8</td>
<td>2 d</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>NCT04339660</td>
<td>China</td>
<td>double arm, triple masking</td>
<td>phase 1/phase 2</td>
<td>Recruiting</td>
<td>UCMSCs</td>
<td>IV</td>
<td>1 or 2</td>
<td>1* 10^6</td>
<td>1 w</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>NCT04490486</td>
<td>USA</td>
<td>double arm, double masking</td>
<td>phase 1</td>
<td>not yet recruiting</td>
<td>UCMSCs</td>
<td>IV</td>
<td>2</td>
<td>1* 10^8</td>
<td>3 d</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>NCT04355728</td>
<td>USA</td>
<td>double arm, triple masking</td>
<td>phase 1/phase 2</td>
<td>Completed</td>
<td>UCMSCs</td>
<td>IV</td>
<td>2</td>
<td>1* 10^8</td>
<td>2 d</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>NCT04392778</td>
<td>Turkey</td>
<td>triple arm, quadruple masking</td>
<td>phase 1/phase 2</td>
<td>Completed</td>
<td>MSCs</td>
<td>IV</td>
<td>3</td>
<td>3* 10^6</td>
<td>3 d</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>NCT</td>
<td>Country</td>
<td>Study Design</td>
<td>Phase</td>
<td>Status</td>
<td>Treatment</td>
<td>Route</td>
<td>Dosage</td>
<td>Duration</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>----------</td>
<td>--------------</td>
<td>-------</td>
<td>---------</td>
<td>-----------</td>
<td>-------</td>
<td>--------</td>
<td>----------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT04565665</td>
<td>USA</td>
<td>triple arm, open-label</td>
<td>phase 1/phase 2</td>
<td>Recruiting</td>
<td>UCMSCs</td>
<td>IV</td>
<td>1 or 2</td>
<td>NM</td>
<td>6 d</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>NCT4888949</td>
<td>Japan</td>
<td>double arm, quadruple masking</td>
<td>phase 2</td>
<td>Recruiting</td>
<td>ADMSCs</td>
<td>IV</td>
<td>4</td>
<td>1* 10 e8</td>
<td>1 w</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>NCT04522986</td>
<td>Japan</td>
<td>single arm, open label</td>
<td>phase 1</td>
<td>Completed</td>
<td>ADMSCs</td>
<td>IV</td>
<td>4</td>
<td>1* 10 e8</td>
<td>1 w</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>NCT04461925</td>
<td>Ukraine</td>
<td>double arm, open-label</td>
<td>phase 1/phase 2</td>
<td>recruiting</td>
<td>PMMSCs</td>
<td>IV</td>
<td>3</td>
<td>1* 10 e6 /Kg</td>
<td>3 d</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>NCT04535856</td>
<td>Indonesia</td>
<td>triple arm, quadruple masking</td>
<td>phase 1</td>
<td>completed</td>
<td>MSCs</td>
<td>IV</td>
<td>1</td>
<td>one arm (low dose group): 5* 10 e7, the other arm (high dose group): 10* 10 e7</td>
<td>no intervals</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>NCT04903327</td>
<td>Brazil</td>
<td>double arm, quadruple masking</td>
<td>phase 2</td>
<td>recruiting</td>
<td>MSCs</td>
<td>IV</td>
<td>3</td>
<td>3* 10 e7</td>
<td>2 d</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>NCT04390152</td>
<td>Colombia</td>
<td>double arm, quadruple masking</td>
<td>phase 1/phase 2</td>
<td>recruiting</td>
<td>WJ-MSCs</td>
<td>IV</td>
<td>2</td>
<td>5* 10 e7</td>
<td>NM</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>NCT04629105</td>
<td>USA</td>
<td>quadruple arm, double masking</td>
<td>phase 1</td>
<td>recruiting</td>
<td>MSCs</td>
<td>IV</td>
<td>3</td>
<td>1* 10 e8</td>
<td>NM</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>NCT04397796</td>
<td>USA</td>
<td>double arm, quadruple masking</td>
<td>Phase 1</td>
<td>active, not yet recruiting</td>
<td>BMSCs</td>
<td>IV</td>
<td>NM</td>
<td>NM</td>
<td>NM</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>NCT04452097</td>
<td>NM</td>
<td>pentad arm, open-label</td>
<td>phase 1/phase 2</td>
<td>not yet recruiting</td>
<td>UCMSCs</td>
<td>IV</td>
<td>1</td>
<td>one arm (low dose group): 0.5* 10 e6 /Kg, the other arm (medium-dose group): 1* 10 e6 /Kg, the other arm (high dose group): 1.5* 10 e6 /Kg</td>
<td>no intervals</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td>NCT04492501</td>
<td>Pakistan</td>
<td>quadruple arm, open-label</td>
<td>not applicable</td>
<td>completed</td>
<td>BMSCs</td>
<td>IV</td>
<td>1</td>
<td>2* 10 e6 /Kg</td>
<td>no intervals</td>
<td>600</td>
<td></td>
</tr>
<tr>
<td>NCT04780685</td>
<td>USA</td>
<td>double arm, quadruple masking</td>
<td>phase 2</td>
<td>recruiting</td>
<td>hMSCs</td>
<td>IV</td>
<td>2</td>
<td>NM</td>
<td>2 d</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>NCT ID</td>
<td>Country</td>
<td>Study Design</td>
<td>Phase/Phase 2</td>
<td>Condition</td>
<td>Tissue/Culture Media</td>
<td>Route</td>
<td>Dose (10^6/Kg)</td>
<td>Interval</td>
<td>Status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>-----------</td>
<td>--------------</td>
<td>---------------</td>
<td>-----------</td>
<td>----------------------</td>
<td>-------</td>
<td>----------------</td>
<td>----------</td>
<td>----------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT04331613</td>
<td>China</td>
<td>single-arm, open-label</td>
<td>phase 1/phase 2</td>
<td>unknown (previously: recruiting)</td>
<td>ESCs</td>
<td>IV</td>
<td>1</td>
<td>escalation (3* 10 e6 /Kg, 5* 10 e6 /Kg or 10* 10 e6 /Kg)</td>
<td>no intervals</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>NCT04345601</td>
<td>USA</td>
<td>double arm, open label</td>
<td>phase 1/phase 2</td>
<td>recruiting</td>
<td>MSCs*</td>
<td>IV</td>
<td>2</td>
<td>1* 10 e8 /Kg</td>
<td>3 to 5 d</td>
<td>66</td>
<td></td>
</tr>
<tr>
<td>NCT04390139</td>
<td>Spain</td>
<td>double arm, quadruple masking</td>
<td>phase 1/phase 2</td>
<td>recruiting</td>
<td>WJ-MSCs</td>
<td>IV</td>
<td>2</td>
<td>1* 10 e6 /Kg</td>
<td>2 d</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>NCT04447833</td>
<td>Spain</td>
<td>single arm, open label</td>
<td>phase 1</td>
<td>active, not yet recruiting</td>
<td>BMSCs</td>
<td>IV</td>
<td>1</td>
<td>(3 patients): 1* 10 e6 /Kg, (number of patients): 2* 10 e6 /Kg</td>
<td>no intervals</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>NCT04398303</td>
<td>NM</td>
<td>triple arm, double masking</td>
<td>phase 1/phase 2</td>
<td>not yet recruiting</td>
<td>UCMSCs</td>
<td>IV</td>
<td>1</td>
<td>one arm (UCMSCs): 1* 10 e6 /Kg, the other arm (only conditioned medium): 100 ml</td>
<td>no intervals</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>NCT04400032</td>
<td>Canada</td>
<td>triple arm, open label</td>
<td>phase 1/phase 2</td>
<td>Completed</td>
<td>UCMSCs</td>
<td>IV</td>
<td>3</td>
<td>one arm: 2.5* 10 e7, the other arm: 5* 10 e7, another arm: 9* 10 e7</td>
<td>1 d</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>NCT04467047</td>
<td>NM</td>
<td>single arm, open label</td>
<td>phase 1</td>
<td>not yet recruiting</td>
<td>MSCs*</td>
<td>IV</td>
<td>1</td>
<td>1* 10 e6 /Kg</td>
<td>no intervals</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>NCT03042143</td>
<td>United Kingdom</td>
<td>double arm, quadruple masking</td>
<td>phase 1/phase 2</td>
<td>active, not yet recruiting</td>
<td>UCMSCs</td>
<td>IV</td>
<td>1</td>
<td>4* 10 e8</td>
<td>no intervals</td>
<td>120</td>
<td></td>
</tr>
<tr>
<td>NCT04269525</td>
<td>China</td>
<td>single arm, open label</td>
<td>phase 2</td>
<td>Recruiting</td>
<td>UCMSCs</td>
<td>IV</td>
<td>4</td>
<td>9.9* 10 e7</td>
<td>2 d</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>NCT04367077</td>
<td>USA</td>
<td>double arm, quadruple masking</td>
<td>phase 2/phase 3</td>
<td>Recruiting</td>
<td>BMAPCs</td>
<td>IV</td>
<td>1</td>
<td>NM</td>
<td>no intervals</td>
<td>400</td>
<td></td>
</tr>
<tr>
<td>NCT04333368</td>
<td>France</td>
<td>double arm, quadruple masking</td>
<td>phase 1/phase 2</td>
<td>Completed</td>
<td>UCMSCs</td>
<td>IV</td>
<td>3</td>
<td>1* 10 e6 /Kg</td>
<td>2 d</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>NCT04371393</td>
<td>USA</td>
<td>double arm, triple masking</td>
<td>phase 3</td>
<td>active, not yet recruiting</td>
<td>MSCs</td>
<td>IV</td>
<td>2</td>
<td>2* 10 e6 /Kg</td>
<td>4 d</td>
<td>223</td>
<td></td>
</tr>
<tr>
<td>NCT04466098</td>
<td>USA</td>
<td>double arm, triple masking</td>
<td>phase 2</td>
<td>active, not yet recruiting</td>
<td>MSCs</td>
<td>IV</td>
<td>3</td>
<td>3* 10 e8</td>
<td>2 d</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>NCT04524962</td>
<td>USA</td>
<td>single arm, open</td>
<td>phase 1/phase 2</td>
<td>Recruiting</td>
<td>MSCs RNA-</td>
<td>NM</td>
<td>1</td>
<td>NM</td>
<td>no intervals</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>IRCT20160809029275N1</td>
<td>Iran</td>
<td>Single arm, Open label</td>
<td>Phase 1</td>
<td>Completed</td>
<td>UCMSCs</td>
<td>IV</td>
<td>1* 10 e6 /Kg</td>
<td>2 D</td>
<td>20</td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Summary of registered clinical trials using stem cell secretome therapy for COVID-19 disease

Abbreviations. No., Number; WJ-MSCs, Warton’s jelly derived mesenchymal stem cells; NM, not mentioned; IV, intravenous; RT-PCR, reverse transcriptase-polymerase chain reaction; NHPBSCs, non-hematopoietic peripheral blood stem cells; SC, stem cell; ADMSCs, adipose-derived mesenchymal stem cells; BMSCs, bone marrow-derived mesenchymal stem cells; hDPSCs, human dental pulp-derived mesenchymal stem cells; MSCs, mesenchymal stem cells; USA, United States of America; DPMSCs, dental pulp derived mesenchymal stem cells; UCMSCs, umbilical cord-derived mesenchymal stem cells; MenSCs, menstrual blood-derived mesenchymal stem cells; hMSCs, human mesenchymal stem cells; ESCs, embryonic stem cells; BMAPCs, bone marrow-derived adult progenitor cells; hEKT-Rex-239, human embryonic kidney T-Rex-239 stem cells; Evs, extracellular vesicles; PMMSCs, placenta-derived multipotent mesenchymal stromal cells
<table>
<thead>
<tr>
<th>No.</th>
<th>Clinical trial identifier</th>
<th>Country</th>
<th>Study design</th>
<th>Study phase</th>
<th>Current status</th>
<th>Source secretome</th>
<th>Route of delivery</th>
<th>Number of doses</th>
<th>Source secretome concentration (cells/ Evs)</th>
<th>Dose intervals</th>
<th>Estimated enrollment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NCT04602442</td>
<td>Russia</td>
<td>triple arm, double masking</td>
<td>phase 2</td>
<td>enrolling by invitation</td>
<td>MSCs exosomes</td>
<td>inhalation</td>
<td>20</td>
<td>0.5 - 2 * 10 e10 / 3ml solution</td>
<td>Q 12 hrs. for 10 d</td>
<td>90</td>
</tr>
<tr>
<td>2</td>
<td>NCT04491240</td>
<td>Russia</td>
<td>triple arm, double masking</td>
<td>phase 1/phase 2</td>
<td>completed</td>
<td>MSCs exosomes</td>
<td>inhalation</td>
<td>20</td>
<td>0.5 - 2 * 10 e10 / 3ml solution</td>
<td>Q 12 hrs. for 10 d</td>
<td>30</td>
</tr>
<tr>
<td>3</td>
<td>NCT04798716</td>
<td>USA</td>
<td>quadruple arm, double masking</td>
<td>phase 1/phase 2</td>
<td>not yet recruiting</td>
<td>MSCs exosomes</td>
<td>IV</td>
<td>3</td>
<td>one arm (3 doses, respectively): 2^* 10 e9, 4^* 10 e9, 8^* 10 e9 /ml, the other arm (3 doses, respectively): 8^* 10 e9, 4^* 10 e9, 8^* 10 e9 /ml</td>
<td>1 d</td>
<td>55</td>
</tr>
<tr>
<td>4</td>
<td>NCT04276987</td>
<td>China</td>
<td>single-arm, open-label</td>
<td>phase 1</td>
<td>completed</td>
<td>MSCs exosomes</td>
<td>nebulization</td>
<td>5</td>
<td>2^* 10 e8 Nano vesicles / 3 ml</td>
<td>1 d</td>
<td>24</td>
</tr>
<tr>
<td>5</td>
<td>NCT05216562</td>
<td>Indonesia</td>
<td>double arm, triple masking</td>
<td>phase 2/phase 3</td>
<td>recruiting</td>
<td>MSCs exosomes</td>
<td>IV</td>
<td>2</td>
<td>NM</td>
<td>6 d</td>
<td>60</td>
</tr>
<tr>
<td>6</td>
<td>NCT04969172</td>
<td>Israel</td>
<td>double arm, double masking</td>
<td>phase 2</td>
<td>active, not recruiting</td>
<td>hEK-T-Rex-239 exosomes overexpressing CD42</td>
<td>inhalation</td>
<td>5</td>
<td>diluted exosomes / 4 ml NS</td>
<td>Q 24 hrs. for 5 d</td>
<td>155</td>
</tr>
<tr>
<td>7</td>
<td>NCT04366063</td>
<td>Iran</td>
<td>triple arm, open-label</td>
<td>phase 2/phase 3</td>
<td>recruiting</td>
<td>MSCs + MSCs Evs</td>
<td>IV</td>
<td></td>
<td>one arm: 2 doses of MSCs, the other arm: 2 doses of MSCs + 2 doses of MSCs Evs (not mentioned Evs numbers)</td>
<td>2 d</td>
<td>60</td>
</tr>
<tr>
<td>8</td>
<td>NCT04493242</td>
<td>USA</td>
<td>triple arm, triple masking</td>
<td>phase 2</td>
<td>completed</td>
<td>BMSCs Evs</td>
<td>IV</td>
<td>1</td>
<td>one arm: 10 ml / 90 ml NS (8^* 10 e11), the other arm: 15 ml / 85 ml NS (1.2^* 10 e12)</td>
<td>no intervals</td>
<td>120</td>
</tr>
<tr>
<td>9</td>
<td>NCT05125562</td>
<td>USA</td>
<td>triple arm, triple masking</td>
<td>phase 2</td>
<td>not yet recruiting</td>
<td>BMSCs Evs</td>
<td>IV</td>
<td>1</td>
<td>one arm: 10 ml / 90 ml NS (7^* 10 e11), the other arm: 15 ml / 85 ml NS (10.5^* 10 e11)</td>
<td>no intervals</td>
<td>30</td>
</tr>
<tr>
<td>10</td>
<td>NCT04753476</td>
<td>Indonesia</td>
<td>double arm, open-label</td>
<td>phase 2</td>
<td>recruiting</td>
<td>hypoxic MSCs secretome</td>
<td>IV</td>
<td>3</td>
<td>1 ml</td>
<td>Q 12 hrs. (every 12 hrs.)</td>
<td>48</td>
</tr>
<tr>
<td>11</td>
<td>NCT05019287</td>
<td>Iran</td>
<td>double arm, double masking</td>
<td>phase 1/phase 2</td>
<td>completed</td>
<td>MenSCs secretome</td>
<td>IV</td>
<td>5</td>
<td>5 ml</td>
<td>1 d</td>
<td>29</td>
</tr>
<tr>
<td>12</td>
<td>NCT05122234</td>
<td>Indonesia</td>
<td>double arm, single masking</td>
<td>phase 3</td>
<td>completed</td>
<td>MSC secretome</td>
<td>IV</td>
<td>1</td>
<td>15 ml / 100 ml NS</td>
<td>no intervals</td>
<td>40</td>
</tr>
</tbody>
</table>
Abbreviations. No., Number; NM, not mentioned; IV, intravenous; RT-PCR, reverse transcriptase-polymerase chain reaction; SC, stem cell; BMSCs, bone marrow-derived mesenchymal stem cells; MSCs, mesenchymal stem cells; MenSCs, menstrual blood-derived mesenchymal stem cells; EVs, extracellular vesicles; the USA, United States of America.

A study referenced as NCT04473170 evaluated the safety and efficacy of nebulized human peripheral blood-derived stem cells (hPBSCs) in treating symptomatic COVID-19-infected patients, and three nebulization methods were assessed. Among nebulization methods, compressor nebulizers preserve the viability of delivered cells without significant loss in their count and morphologic changes. The mentioned study depicted application of hPBSCs has significant improvements in clinical outcomes of the treated group with a 28-day survival rate of 94.20%. In addition, there was no significant difference in adverse effects between the control and hPBSCs treated groups [50][51].

Another study referenced as NCT04355728 investigated the safety and efficacy of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) in treating severe complications of acute lung injury (ALI) and ARDS, completed the phase 1/phase 2 trial on 24 patients. The mentioned clinical trial demonstrated that hUC-MSCs treatment would not increase the adverse events with a hazard ratio of 8.76% (95% confidence interval [CI]:1.07-71.4) and a 31-day survival rate of 91% [52]. A completed clinical trial referenced as NCT04491240 investigating the safety and efficacy of two types of inhaled MSCs exosomes in treating severe hospitalized patients with COVID-19 completed the phase 1/phase 2 trials on 30 patients; reported any severe adverse events in MSCs exosomes treating groups [53].

A completed clinical trial referenced as NCT05019287 assessing the safety and efficacy of allogenic menstrual blood-derived mesenchymal stem cells secretome (MenSCs secretome) infusion in treating severe hospitalized patients with COVID-19, completed the phase 1/phase 2 trial on 29 patients; demonstrated that intravenous injection (IV) of MenSCs secretomes could improve oxygen levels in 60% of intervention group, decrease radiologic pulmonary involvement and mortality rates. There were no infusion-related adverse events in MenSCs secretomes treated groups with a survival rate of 57% [54].

A study was conducted by Li et al. to assess the effect of invariant natural killer T cells (iNKT) on SARS-CoV-2 infection. They produced allogeneic hematopoietic stem cell-engineered iNKT cells (AlloHSC-iNKT) through T cell receptor (TCR) engineering of human cord blood CD34+ hematopoietic stem cells (HSCs) and differentiation of these HSCs into iNKT cells in an ex vivo HSC-Derived iNKT Cell Culture. The results showed that these AlloHSC-iNKT cells killed SARS-CoV-2 infected cells and eliminated SARS-CoV-2 infection-stimulated inflammatory monocytes. In addition, the AlloHSC-iNKT cells were resistant to T cell-mediated alloreaction and did not cause GVHD [55].

In another study, Liao et al. evaluated the safety and efficacy of interleukin-18-primed hUC-MSCs application in an in vivo model of lung injury. This study demonstrated an efficient effect of IL-18-primed hUC-MSCs therapy than non-primed hUC-MSCs therapy alone. They found that in the IL-18-primed hUC-MSCs group, the immunosuppressive effect of CD3+ T cells is more prominent. In addition, the IL-18-primed hUC-MSCs expressed higher levels of VCAM-1, MMP-1, TGF-β1,
CCL2, and CXCL12. Also, the in vivo IL-18-primed hUC-MSCs therapy had promising results in improving the clinical symptoms of pre-clinical viral lung injury cases\(^\text{[56]}\).

Also, two separate studies evaluated the in vitro effect of MSCs-derived exosomes. Hussein et al. conducted a study to evaluate the effect of Human Wharton’s Jelly Mesenchymal Stem Cells Secretome (hWJ-MSC-S) on an in vitro model of SARS-CoV-2 infection. The results showed a significant reduction in viral infection as a promising way to overcome SARS-CoV-2 infection and its complications\(^\text{[57]}\). In addition, in 2022, a study was conducted to evaluate the anti-SARS-CoV-2 effects of extracellular vesicles (EVs) released from MSCs that were applied to in vitro anti-SARS-CoV-2 assays. The result was suppression in viral replication.

The potential and safety of ADMSCs were documented by Sanchez-Guijo et al. examined 13 adult patients with COVID-19 who underwent invasive mechanical ventilation and were previously treated by antiviral and anti-inflammatory interventions. The administered dose of ADMSCs was 0.98×10^6 cell/kg body weight (BW). The results demonstrated no complications associated with MSC therapy, and clinical improvement was seen in about 70% of the patients discharged from the ICU. Moreover, the MSC therapy elevated the lymphocyte count and reduced the levels of inflammatory markers including CRP, IL-6, ferritin, LDH, and D-dimer; therefore, they suggested the ADMSCs therapy as a safe approach with promising clinical outcomes in COVID-19 patients\(^\text{[58]}\).

Further studies need to be conducted to optimize MSCs-based therapies in moderate to severe cases of COVID-19 infection, in terms of the number of cells, administration intervals (single or multiple infusion), source of MSCs, local (inhalational or nebulized) or systemic route of administration\(^\text{[11],[36]}\).
4. Human-induced pluripotent stem cells (hiPSCs)

Adult human somatic cell reprogramming to generate iPSCs using transcription factors was performed by Takahashi et al.\textsuperscript{[59]}. It was reported that iPSCs could be generated from a patient's specific somatic cells to be used in various diseases as an in-vitro disease model\textsuperscript{[60][61]}. One of the recent advances is the somatic cell-derived iPSCs with different clinical applications. The production of iPSCs, an effective cell source in cell therapy, occurs with the entry of a certain class of reprogramming agents into somatic cells \textsuperscript{[26][60]}. Stem cells have been able to restore sperm count in some differentiation studies, so a significant increase was reported in the survival pathways and anti-apoptotic protein expression \textsuperscript{[62]}. Compared to the extraction and employment of embryonic stem cells (ESCs), iPSCs have fewer ethical issues, particularly for autologous stem cell therapy. These cells and ESC-like cells have limited differences in gene expression patterns \textsuperscript{[63][64]}. These cells have the potential for clinical applications and can be produced in different ways. However, the employment of retroviral and lentiviral vectors and proto-oncogenes, such as KLF4 and c-Myc, as well as the approaches applied to reprogram the cells, may impair the developmental characteristics and clinical application of these cells \textsuperscript{[65]}. Anyone with a specific phenotype or genotype can donate hiPSCs for in vitro disease modeling. Differentiated cell types of a particular disease can be achieved from patient-derived hiPSC models. For example, hiPSC-derived cardiomyocytes or neurons can help understand the pathogenesis of particular diseases and screen for the choice of drug \textsuperscript{[66]}. One of the most valuable models for infectious diseases has been reported to be hiPSC-derived cells. Furthermore, the mixture of human iPSC with recent advancements in the field of gene editing and 3D organoids makes iPSC-based platforms more efficient in every area of their usage such as precision medicine \textsuperscript{[67]}. The hiPSC can cover human genetic diversity. Despite its ability to produce different types of human cells, it can be used in the drug-production process \textsuperscript{[68][69]}. A study summarized the cytopathogenic impacts and cytokine/chemokine response in hiPSCs-derived cardiomyocytes in an in vitro model of SARS-CoV-2 myocarditis, suggesting an opportunity for drug screening \textsuperscript{[6]}. Huang et al developed an in vitro study evaluating the key signaling pathway in commencing the SARS-CoV-2 infection as well as assessing the efficacy of anti-viral drugs on the lung organoid platform with air-fluid culture method. iPSC-derived alveolar type 2 pneumocyte (AT2) is one of the progenitors of respiratory epithelium that can be infected by SARS-CoV-2. The aforementioned study depicted the predominance of nuclear factor kappa B (NF-κB) signaling in the first hours of viral invasion as the core inflammatory signaling pathway \textsuperscript{[70]}. Various studies evaluated the viral replication inhibitory effects of different anti-viral drugs such as Remdesivir and transmembrane protease, serine 2 (TMPRSS2) inhibitor on the SARS-
CoV-2 infected models of iPSC-derived lung cells [71][72]. As seen in Figure 2, there are also reports of the ability of lung epithelial cell-derived hiPSCs to produce a sensitive model of SARS-CoV-2 infection and drug screening [73][74]. Several studies conducted on lung organoids, intestinal organoids as well as cardiomyocytes iPSCs models and iAT2 iPSCs models as platforms to evaluate the pathophysiology of the SARS-CoV-2 infection mechanisms [74].

5. Mesenchymal Stem Cells (MSCs)

The MSCs are fibroblast-like cells with the capacity to attach to plastic surfaces and proliferate in vitro that can be isolated from various sources of fetal or adult tissues [41][75]. Different tissues can be used as a source to isolate the MSCs, depending on the practical, logistical, and in vitro properties of the source. Some of these sources are dental pulp, endothelial progenitor cells, umbilical cord blood, adipose tissue, umbilical cord stroma, and bone marrow [33][41]. Adult adipose-derived MSCs (ADMSCs) can repair tissues due to their ability to proliferate for a long time without differentiation [76].

The ability for proliferation and regeneration of MSCs is almost indeterminate and could be potentially used for stem cell therapy in the COVID-19 treatment [77][78]. In response to harsh environmental conditions at the target site, the autophagic and apoptotic processes of MSCs occur, which eventually results in the release of growth factors and cytokine-rich exosomes, which can reduce disease pathophysiology. Thus, this has shed light on new therapeutic approaches concerning stem cell derived as a new modality to address the challenges which are associated with parent cells. Additionally, MSCs are also capable of inhibiting the abnormal activation of T lymphocytes and macrophages, as well as inducing the differentiation of regulatory T cells (Tregs) and anti-inflammatory macrophages [78][79].

Multiple processes are accelerated in the presence of MSCs through some pathways such as chemical absorption, anti-scarring, supporting the growth and differentiation of local stem and progenitor cells, angiogenesis, anti-apoptosis, and immunomodulation [80] through immunomodulation; MSCs could play a role in the repairing and regenerating process in many pathological lung diseases, including idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, acute lung injury, asthma, and bronchopulmonary dysplasia [81].

6. The hiPSCs and hPSCs as Invitro models for COVID-19 treatment

Several limitations became apparent in primary laboratory studies for modeling SARS-CoV-2 as a complex human respiratory disease. Although the drug’s effects can be determined directly through patient cells, there are limitations to the availability and expansion capacity of these cells compared to tumor-derived cell lines or immortalized and transformed cells. Besides, genetic, and metabolic abnormalities can be a barrier to proper drug screening. Therefore, human cell models must be physiologically appropriate to find out the pathophysiology of SARS-CoV-2, which facilitates drug analysis [73].

The literature review showed that most researchers extracted lung epithelial lineage from hiPSC using a directed
differentiation method as a human model through a three-step protocol [82][83]. A microenvironment was remodeled by Activin-A/BMP4 integration to interact with mesenchymal and epithelium cells. Subsequently, the expression of NKX2.1, the main transcription factor in the generation of lung epithelial lineage, was enhanced by increasing the levels of growth factors (EGF and bFGF). Moreover, the proximal airway epithelial cells were generated increasingly by adding retinoic acid (RA), activating KGF1 and WNT pathways, and blocking MAPK and BMP4 pathways. The anterior-posterior endodermal fate was strongly affected by the Wnt/β-catenin signaling pathway, FGF10, and the lung bud formation and development [84].

Two-dimensional cultured cell lines are the current in vitro systems to investigate different coronaviruses’ behavior and drug responses. Because of differences in the infectivity rate of SARS-CoV-2 among different ethnic people, the application of a three-dimensional human lung organoid (3D-HLO) model isolated from iPSCs of various populations has been suggested recently. The 3D-HLO systems can optimally mimic the normal lung tissue of human beings. The challenge of severity/infectivity rate in human populations precludes the suggestion of animal models as the best option for such studies [85]. Dye et al. designed a 3D-HLO model for adult airways that uses poly (lactide-co-glycolide) (PLG) or polycaprolactone (PCL) scaffolds for HLO transplantation. This protocol provides a porous and degradable scaffold for HLO, so it assists tissue maturation and is an appropriate model for adult airways [86].

In a study by Zhou et al., the iPSCs-derived organoids were introduced as an appropriate infection model to mimic the viral life cycle and drug screening under ex vivo conditions. The human iPSC-3D organoids from self-organized tissues having multiple cell environments are functionally and structurally similar to real human organs, thereby providing more efficient viral infection, mimicking regular host-virus interaction, and allowing long-term experiments. A functional hiPSC-derived organoid has been introduced as a feasible and reliable ex vivo model of infection for virological studies, which allows the study of the critical molecular dynamics of SARS-CoV-2 to develop effective treatment and prevention strategies [87].

The researchers developed a platform utilizing system-wide human cell lineages and organoids. They found that both pseudo-entry and live SARS-CoV-2 could infect liver organoids, alpha and beta cells of the pancreas, heart cells, and dopaminergic neurons. As it is still unknown that SARS-CoV-2 can be vertically transmitted to fetuses, there is a controversy about using hPSC-derived cells to model SARS-CoV-2 infection [88][89].

In a study, Yang et al. [90] assessed the infectivity rate of human cells with SARS-CoV-2 infection via a library generated from hPSC-derived cells and organoids, such as dopaminergic neurons, cortical neurons, microglia, macrophages, cardiomyocytes, endothelial cells, liver organoids, and pancreatic endocrine cells. These results demonstrate that pancreatic, hepatic, and cholangiocyte cells derived from hPSCs are permissive to SARS-CoV-2 infection, as confirmed by adult human islets, liver, and cholangiocyte organoids, as well as a humanized mouse model [90].

The expression of chemokine was upregulated according to the determination of transcript profiles in the hPSC-derived liver organoids and pancreatic endocrine cells infected by SARS-CoV-2, in line with tissue profiling following the autopsy of COVID-19 patients [91]. Low or no permissiveness to both pseudo-entry and live SARS-CoV-2 was interestingly reported
for some ACE2-expressing cells by analyzing a human lung single-cell sequencing dataset (GSE132914) for the levels of expression of ACE2 and transmembrane serine protease 2 (TMPRSS2), the two receptors that are the primary sites of entry for the SARS-CoV-2 [92].

Including cortical neurons, macrophages, and endothelium, which means factors other than ACE2 are also involved in virus penetration (such as TMPRSS2). The need to replace ACE2-overexpressing cells with hPSC-derived primary-like cells is highlighted in the SARS-CoV-2 biology by looking at the nonlinear relationship between permissiveness to SARS-CoV-2 infection and ACE2 [93]. According to these researchers, drug screening and evaluation of possible antiviral drugs can be done directly using protocols based on disease-relevant human cells/organoids [89].

7. Clinical application of MSCs in the treatment of COVID-19

Much attention has recently been drawn to MSC-based therapies due to their self-renewable capacity and pluripotency [94][95]. The immunoregulatory activity of MSCs mitigates body inflammation via immunosuppression [96][97], which can be a promising possible approach for the treatment of COVID-19 [98]. In an in vitro study, MSCs expressing anti-viral properties including upregulation of genes resulting in encoding proteins responsible of preventive effects on host cell viral invasions [99]. According to recent findings, there were no critical adverse events, such as ventricular tachycardia, cardiac arrhythmia, and hypoxemia, in nine ARDS patients receiving allogeneic MSCs transplantation [100].

The MSCs-based therapy for SARS-CoV-2 was reported to be effective and safe, although further clinical trials with prolonged follow-up duration are needed to detect the long-term impacts of the treatment on patients with COVID-19 [101]. Chrzanowski et al. reported that the MSCs could repair damaged tissue rapidly owing to their regenerative potential and prevent long-term COVID-19-related lung injuries [7]. In the severe SARS-CoV-2 infection, the respiratory alveolars infiltrated with various immune cells such as neutrophils, macrophages, NK cells, and T cells leading to high concentrations of inflammatory cytokines and hypercytokinemia. The ultimate consequence of severe infection is alveolar lung fibrosis. The MSCs can stabilize the leakage of endothelial fluid and maintain the activity of the alveolar-capillary barrier. These stem cells can be attracted to the inflammatory sites due to different chemokine secretions, and subsequently transform the overreaction of the inflammatory response. MSCs can ameliorate respiratory alveolar fibrosis due to their regenerative and differentiating characteristics [37]. Several studies evaluating the pathophysiology, molecular signaling, and underlying cellular mechanisms revealed that MSCs can alter the course of moderate to severe COVID-19 infection by following pathways including, decreasing recruited cellular apoptosis, direct and indirect immune defense enhancement via secretion of anti-pathogenic peptides and activating phagocytic immune cells, ameliorating oxidative stress, alveolar epithelial regeneration, decreasing the alveolar-capillary permeability and enhancing alveolar fluid clearance [36]. The ameliorating effect of inflammatory cascades is mostly assigned to the paracrine-releasing factors derived from MSCs, therefore some studies investigated MSCs’ conditioned medium application in in vitro alveolar injury models [102][103]. Due to the lower chance of MSC engraftment, some studies evaluated the therapeutic potentials of MSCs’ EVs in ALI models [104][105] as well as clinical trials conducted on COVID-19 patients [57][106].
ADMSCs are one of the MSCs’ sources, applied in the several clinical trials evaluating that of safety and efficacy on moderate to severe COVID-19 patients (Table 1). The rationale of selecting the aforementioned source of MSCs can be due to less invasiveness of harvesting adipose tissue as well as their higher proliferative ability. ADMSCs as one of the stromal vascular fractions of human adipose tissue, can have potential anti-viral properties, immunomodulatory effects as well as inhibitory characteristics on tissue’s structural remodeling. The tissue remodeling process in viral infection can be inhibited via increasing secretion of tissue inhibitors of metalloproteinases using ADMSCs[^99][^107][^108].

A study conducted by Ren et al. depicted that the lung epithelial cells are protected against oxidative stress-induced cell death by delivering miR-21-5p via the MSC exosomes[^109]. Bari et al. demonstrated that Alpha-1-antitrypsin (AAT) was present on the surface of exosome-derived MSCs[^110]. The anti-inflammatory and immunomodulatory effects of AAT enhanced the protection of lung epithelial cells by inhibiting neutrophil-derived proteolytic enzymes, reducing inflammation-imposed lung permeability, and declining interstitial lung edema[^110][^111].

Chrzanowski et al. examined female cases with intravenous MSC transplantation (1×10^6 per kg) in lung tissue in comparison with female placebo controls; they observed a significant improvement in pulmonary function. In addition, a significant reduction was seen in tissue inflammation in the intervention group[^7].

Although, Several studies support the evidence that MSCs can be a suitable candidate for controlling and treating hypercytokinemia-induced SARS-CoV-2 infection and ALIs due to their critical immunomodulatory, anti-inflammatory, and regenerative properties, respectively[^42]. There are challenges in optimizing the engraftment and survival of applied MSCs. Several studies overcoming these challenges by modifying gene expression to improve MSCs homing or even increasing the anti-inflammatory properties in ALI models[^36]. Overexpression of Chemokine receptor 4 (CXC4), chemokine receptor 7 (CXC7), and E-prostanoid 2 (EP2) can enhance MSCs migration into the injured respiratory sites[^112][^113][^114]. Heme oxygenase-1 (HO-1) overexpression in MSCs regulates inflammatory cytokine concentration[^115].

The clinical trial launched in 2020 to investigate MSC therapy for COVID-19 management revealed a significant elevation in the count of regulatory dendritic cells (DCs) following MSC transplantation[^116]. Regulation of the immune system by regulatory DCs is essential to maintaining immune homeostasis by inducing the expression of immunosuppressive cytokines like IL-10 and TGF-β and thus preventing the lungs from the detrimental effects of macrophage and DC-driven systemic immune responses. In addition, the COVID-19 patients with MSC transplantation showed an elevation in IL-10 level and a reduction in TNF-α level compared to controls[^117]. Furthermore, it is demonstrated that MSC therapy for ARDS caused by H9N2 avian influenza viruses and H5N1 infections results in reduced pulmonary inflammation and lung injuries[^1][^118].

In a case series by Yao et al., the efficacy of hUC-MSCs therapy was assessed. 5 patients with severe COVID-19 infection went through the salvage therapy of hUC-MSCs intravenous infusion. The results showed a significant advance in laboratory biomarkers and lung computed tomography scan (CT-Scan) images in all patients[^119].

In addition, two cases were reported by Kim et al. and Balzanelli et al. The first was at Wonju Severance Christian
The patient was a 73-year-old man with positive real-time PCR that developed ARDS. Allogenic human bone marrow-derived mesenchymal stem cell (hBMSC) was administered intravenously and, the clinical symptoms, signs, and laboratory findings, including PaO2/FiO2 and O2 saturation, were improved\textsuperscript{[120]}. The second case was a 56-year-old man with a positive PCR test for COVID-19 infection who received Peripheral Blood Stem Cells and Plasma (PB plasma/SCs). No adverse effects were reported during PB plasma/SCs administration. Also, CT showed a 98% reduction in lung damage after a total of five plasma transfusions\textsuperscript{[121]}.

Shu et al. evaluated the safety and efficacy of UC-MSCs administration in the management of COVID-19. They found the hUC-MSC therapy as an excellent, effective achievement with clinical values. Moreover, the hUC-MSC therapy group exhibited a significant alleviation in chest tightness, dyspnea, and fatigue, in a shorter time compared to the controls\textsuperscript{[122]}.

Although, multiple MSC-related studies are being performed on COVID-19 patients with respiratory complications. Few reports demonstrate the ability of these therapies to promote recovery and survival in these patients. A systematic review included 8 MSCs randomized clinical trials revealed that MSC therapy in COVID-19 cases can reduce mortality rates, and hospital stay and significantly decrease the sensitive marker of inflammation and host-cytokine production response\textsuperscript{[123]}. It can be reasoned that variable factors including the number of applied MSCs, route of administration, cell infusion intervals, and source of applied MSCs, could play a part in these studies’ results\textsuperscript{[36][124][125]}. Antebi et al. depicted that autologous transplantation of BM-MSCs which are harvested from an ARDS patient, can affect the immunoregulatory properties of harvested MSCs. Although inconclusive evidence is available to support optimized sources of MSC-based therapies for relieving COVID-19 respiratory complications. Further studies need to be conducted to optimize MSC-based therapy protocols. MSCs route of administration is another factor to be considered in the interpretation of study results. Miller et al. depicted that intravenous application of MSCs can significantly decrease ECMO flow due to cell adherence to the oxygenator membrane. Indicating the MSCs intravenous injection before the ECMO application. Local administration of MSCs via inhalational route can increase the number of transplanted MSCs in the site of injury in ARDS cases and genetic modification can help to enhance cell engraftment and survival. Several concerns and ethical issues raised in the matter of stem cell-derived product application that needs institutional and legislative supervision. The aforementioned concerns can be included as the alterations in biological activity, purification of stem cell-derived products in each cultural batch, and the possibility of adverse and allergic reactions to the remanent cultural media\textsuperscript{[126]}. Despite an urgent need to develop MSC-based therapies during the COVID-19 pandemic, MSC production must be under Good Manufacturing Practices (GMP) and must follow human use regulations before adoption\textsuperscript{[36][125]}.

8. Conclusion

Consistent with the findings of the present review article, studies are still ongoing to support stem cell and stem cell-derived strategies as valuable tools for the treatment of COVID-19. There is little evidence so far about the safety and efficacy of such treatments in the short term, at least in severe and very severe patients. Mesenchymal stem cells and Human-induced pluripotent stem cells are promising candidates for developing new therapies for COVID-19.
Due to their ability to produce disease-related differentiated cells, these stem cells can be exploited to approve large-scale antiviral drugs as an in vitro model system to scrutinize the biology of virus-host interaction. The complexity and high cost of cell therapies emphasize the careful evaluation of such treatment strategies concerning sensitive parameters, including ICU time, recovery time, and length of hospital stay. Advanced therapies are hardly a suitable candidate for controlling the pandemic, but they can still help rescue patients in severe or very severe conditions.

Statements and Declarations

Funding

Not applicable

Conflicts of interest/Competing interests and Author Disclosure Statement

The authors declare no competing interests.

References


36. ^Hua Q, Andong Z. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. Protein & Cell. 2020;707-22.


85. a Bose B. Induced Pluripotent Stem Cells (iPSCs) Derived 3D Human Lung Organoids from Different Ethnicities to Understand the SARS-CoV2 Severity/Infectivity Percentage. Stem Cell Reviews and Reports. 2020:1-3.


93. a Yangou L, Davis RP, Mummery CL. Using Cardiovascular Cells from Human Pluripotent Stem Cells for COVID-19


